Clinical Trials · NCT05056246

Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants

Name: Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Maridebart cafraglutide

Phase: Phase 1
Recruitment status: Completed
Sponsor: Amgen
Enrollment: 34
Start date: Sep 2021
Locations: 1 site, United States
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Intact AMG 133

View Maridebart-Cafraglutide compound reference